Xencor, a clinical-stage biotech developing treatments for severe autoimmune and allergic diseases and cancer, filed on Friday with the SEC to raise up to $69 million in an initial public offering. The Monrovia, CA-based company, which was founded in 1997 and booked $9 million in collaboration revenue for the 12 months ended June 30, 2013, plans to list on the NASDAQ under the symbol XNCR. Xencor initially filed confidentially on September 11, 2013. Credit Suisse and Leerink Swann are the joint bookrunners on the deal. No pricing terms were disclosed.
